Lipoxin <scp>A</scp>₄ suppresses the development of endometriosis in an <scp>ALX</scp> receptor‐dependent manner via the p38 <scp>MAPK</scp> pathway

Abstract

LXA4 exerted anti-inflammatory, anti-proliferative and anti-invasive effects on endometriosis through a mechanism that involved down-regulating the activities of p38 MAPK, which was mediated by ALX receptors.